ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte's commercial ope ...

I've been following MaxCyte, Inc. ( MXCT ) for years now, since they IPO'ed on the London exchange (LSE: MXCT ). About a year ago, I wrote about MaxCyte's unique business model Jonquil Capital is a private investor, investment analyst, and writer from Smyrna, Georgia - the Jonquil city.Hopefully, by putting some words down in a page I can clarify my own thoughts on investment ideas and inspire worthwhile discussion and debate about the merits of these investments. I've been fully indoctrinated into the valu ...

ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of nextgeneration cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) ...

ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the Virtual Craig-Hallum Capital Group Bioprocessing Conference on Thursday, September 19th at 9:30 am ET. A replay link of the event ...

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 35.71%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.09, delivering a surprise of 35.71%. Over the last four quarters, the company has surpassed ...

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, August 6, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cellengineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced its financial results for the second quarter ended June 30, 2024, and updates its 2024 guidan ...

ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the second quarter 2024 after the U.S. market close on Tuesday, August 6th, 2024. Company management will host a conference call to disc ...

The average comprises four short-term price targets ranging from a low of $7 to a high of $11, with a standard deviation of $2.06. While the lowest estimate indicates an increase of 40% from the current price level, the most optimistic estimate points to a 120% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. Price, Consensus and EPS Surprise Accordi ...

Core Viewpoint - MaxCyte, Inc. (MXCT) is identified as a strong candidate for trend investing due to its solid fundamentals and positive price momentum [2][4][11]. Group 1: Price Trends - MXCT has experienced a price increase of 4.8% over the past four weeks, indicating that the upward trend is still intact [3]. - Over a 12-week period, MXCT has gained 11.1%, reflecting investors' willingness to pay more for its potential upside [8]. - Currently, MXCT is trading at 82.3% of its 52-week high-low range, suggesting it may be on the verge of a breakout [9]. Group 2: Fundamental Strength - The stock carries a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [4]. - MXCT has an Average Broker Recommendation of 1 (Strong Buy), indicating high optimism from the brokerage community regarding its near-term price performance [5]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for identifying stocks like MXCT that have sufficient fundamental strength to maintain their recent uptrend [7]. - The Zacks Rank stock-rating system has a strong track record, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [10].

ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th at 2:40 pm CT. A live and archived webcast of the event wi ...